share_log

The Daily Biotech Pulse: Pfizer-BioNTech's COVID-19 Booster For Kids 5-11 Coming Soon, Ultragenyx In-Licenses Gene Therapy For Genetic Disorder, Ampio's AP-013 Trial Under Independent Investigation

The Daily Biotech Pulse: Pfizer-BioNTech's COVID-19 Booster For Kids 5-11 Coming Soon, Ultragenyx In-Licenses Gene Therapy For Genetic Disorder, Ampio's AP-013 Trial Under Independent Investigation

每日生物技術脈搏：輝瑞-BioNTech 的 COVID-19 兒童版 Booster 即將上市，Ultragenyx 批准了遺傳性疾病基因療法，Ampio 的 AP-013 試驗正在獨立調查中
Benzinga Real-time News ·  2022/05/17 21:09
Here's a roundup of top developments in the biotech space over the last 24 hours:
以下是過去 24 小時內生物技術領域的主要進展摘要：
Stocks In Focus
焦點股票
FDA May Authorize Pfizer-BioNTech's COVID-19 Booster For 5-11 Year Kids Soon: NYT
美國食品藥品管理局可能很快批准輝瑞-BioNTech 爲 5-11 歲兒童推出 COVID-19 增強劑：紐約時報
The FDA is expected to authorize a booster shot of Pfizer Inc (NYSE:PFE)/BioNTech SE's (NASDAQ:BNTX) COVID-19 vaccine for children ages 5 to 11, likely Tuesday, the New York Times reported, citing people familiar with the matter.
預計美國食品藥品管理局將批准加強注射輝瑞公司（紐約證券交易所：PFE）/BioNTech SE（納斯達克股票代碼：BNTX）《紐約時報》援引知情人士的話報道，可能在週二爲5至11歲兒童接種 COVID-19 疫苗。
It is unclear how much demand there is for the third dose in the age group. According to the U.S. Centers for Disease Control and Prevention, just 28.8% of children ages...
目前尚不清楚該年齡組對第三劑的需求有多大。根據美國疾病控制與預...
登入免費觀看全文
登入/註冊

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論